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Abstract
Iran is known as an endemic country for hepatitis E 
virus (HEV) infection, while there are variations in 
the epidemiology of HEV infection throughout the 
country. The available epidemiological studies in 
different regions of Iran show HEV seroprevalence 
of 1.1%-14.2% among general population, 4.5% 
-14.3% among blood donors, 6.1%-22.8% among 
injecting drug users, 6.3%-28.3% among hemodialysis 
patients, 1.6%-11.3% among patients infected 
with other hepatitis viruses, 27.5% among patients 
with chronic liver disease, 30.8% among kidney 
transplant recipient patients, and 10%-16.4% among 
human immunodeficiency virus-infected patients. 
These variations reflect differences in the status of 
public health and hygiene, risk factors, and routes 
of transmission in different regions and groups. 
Therefore, it is necessary to review the epidemiology 
of HEV infection to determine the most prevalent risk 
factors and routes of transmission, and to evaluate 
the effectiveness of preventive strategies employed 
in the public health services of the country. Moreover, 
the other epidemiological aspects of HEV, including the 
genotypic pattern, extra hepatic manifestations, and 
incidence of chronic infection need to be investigated 
among Iranian population to expand the current 
knowledge on the epidemiology of HEV and to clarify 
the real burden of HEV infection. Therefore, this review 
was performed to provide a general overview regarding 
the epidemiology of HEV in Iran. 
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Core tip: Iran is considered as an endemic country 
for hepatitis E virus (HEV) infection, while there are 
variations in the epidemiology and prevalence of 
hepatitis E throughout the country. These variations 
reflect differences in the life styles, status of public 
health, risk factors, and routes of transmission in 
different groups and geographical regions of Iran. 
Therefore, this study was conducted to review the 
epidemiological aspects of HEV infection in Iran. 
Taherkhani R, Farshadpour F. Epidemiology of hepatitis E 
virus in Iran. World J Gastroenterol 2016; 22(22): 5143-5153 
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v22/i22/5143.htm  DOI: http://dx.doi.org/10.3748/wjg.v22.
i22.5143
INTRODUCTION
Hepatitis E virus (HEV) is the causative agent of 
hepatitis E infection[1]. This infection is usually 
asymptomatic or acute self-limiting[1] but might lead 
to fulminant hepatitis or even long-term chronic 
infection and cirrhosis with a high rate of mortality 
due to severe liver failure in high-risk groups, such as 
pregnant women, organ transplant recipient patients, 
immunocompromised patients, and those with pre-
existing liver problems[1-6]. HEV is predominantly 
transmitted via the fecal-oral route; however, trans-
mission of HEV through blood transfusion, organ 
transplantation, hemodialysis, placenta and sexual 
intercourse is also possible[1,7,8]. Among these, sexual 
transmission of HEV is less common and has mostly 
been reported in homosexual males[7,9]. 
HEV is a small spherical virus with a positive-
sense RNA genome and an icosahedral non-enveloped 
capsid[5,10-12]. The viral genome contains three partially 
overlapping open reading frames[5,13,14]. HEV has 
been classified into the family Hepeviridae, the genus 
Orthohepevirus, and the species Orthohepevirus 
A[1,15]. There are four genotypes of HEV capable of 
causing human infection with different epidemiological 
features[3,16]. These genotypes have further been 
subdivided into 24 subgenotypes[5,17,18]. Genotypes 
1 and 2 are only recognized in human beings, 
while genotypes 3 and 4 are found in domestic 
and wild animals as well[7,19-21]. Despite this genetic 
heterogeneity, only one serotype has been recognized 
so far[1,5,22]. 
HEV genotypes differ in their severity, patho-
genecity, mortality rates, mode of transmission, age 
distribution, and geographical distribution[1,7-9,23]. HEV 
genotype 1 is frequently found in North Africa and 
Asia[9]. HEV genotype 2 is more common in West 
Africa and Mexico[7,9]. HEV genotype 3 is considered to 
have a worldwide distribution and is more prevalent 
in several European and American countries, as well 
as Japan, China, Australia, and New Zealand[7,9,10]. 
HEV genotype 4 has been reported in Asian countries 
and more recently in Central Europe[5,9,23]. Genotypes 
3 and 4 appear to be less virulent than genotypes 
1 and 2[1,24]. HEV genotype 1 is associated with the 
most cases of fulminant hepatitis and high mortality 
during pregnancy[8,10]. While HEV genotype 3 is the 
cause of almost all cases of chronic HEV infections 
worldwide[5,7,8]. Infection with HEV genotype 4 seems to 
be asymptomatic and mostly remains undiagnosed[6,9].
Hepatitis E is usually an asymptomatic or acute 
self-limited infection and only requires supportive care. 
However, when fulminant or chronic hepatitis arises, 
therapeutic intervention is an obligation[9,10]. Reduction 
of immunosuppressive therapy is considered as the 
first-line therapy in immunocompromised patients 
with chronic HEV infection. Nevertheless, at the same 
time, it can increase the risk of graft rejection[3,5,9,25-27]. 
In such conditions, organ transplant recipient patients 
benefit most from antiviral therapy, including pegylated 
interferon (peg-IFN) monotherapy or combination 
therapy with ribavirin and peg-IFN[3,10,25]. 
These antiviral agents are associated with severe 
side effects. IFN-therapy may result in acute graft 
rejection[3,5,8,25]. Ribavirin administration induces severe 
hemolytic anemia; and when the dose of ribavirin 
is reduced, the viral clearance is not achieved[8]. 
Therefore, the combination of ribavirin with a reduc-
tion in the doses of immunosuppressive drugs has 
been found to be the most promising treatment 
option[5,10,25]. In addition, these antiviral drugs should 
be administered with caution during pregnancy due 
to their teratogenicity[10,27,28]. Early delivery of fetus 
or termination of pregnancy should be considered 
as another option to save mothers’ lives[28,29]. Ad-
ministration of the antiretroviral drugs in human 
immunodeficiency virus (HIV)-positive patients can 
result in an increase in the proportion of T helper cells 
and subsequently clearance of HEV infection[25].
Considering the side effects and limitations of the 
currently available treatment regimens as well as 
the absence of a specific antiviral treatment for HEV 
infection, preventive measures and vaccination against 
HEV infection are the most desirable approaches for 
controlling HEV infection[25,30]. HEV vaccines using 
the truncated forms of capsid protein have been 
evaluated in human clinical trials, and one of them, 
HEV 239 vaccine, has been approved in china in 2011. 
Although this vaccine has shown promising results, 
it is not commercially available worldwide[5,20,27,31]. 
Therefore, preventive measures are still known to 
be the best option. Providing clean drinking water 
supplies, improving the hygienic infrastructure and 
sanitary status, washing hands and vegetables 
properly, boiling drinking water, and avoiding con-
sumption of undercooked foods and unpeeled fruits 
are some of these preventive measures[1,5,11,23,31,32]. 
In addition, proper chlorination of water supplies, 
sanitary preparation of food, and public awareness 
regarding the possible routes of HEV transmission are 
essential to reduce the risk of exposure to HEV in the 
community[1,11,23]. 
HEV has infected one-third of the world’s popu-
lation[13,17]. In addition, 20 million new cases and 3.3 
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million acute cases of HEV infection occur globally each 
year[3,33], and HEV-related hepatic failure is responsible 
for approximately 56600 deaths per year[33,34]. The 
mortality rate of HEV infection is 1%-2% in the general 
population[17], but it may rise to 10%-25% in pregnant 
women[7,20] and over 75% in individuals with pre-
existing liver problems[20]. 
HEV is a considerable global health concern. 
Although HEV infection was traditionally believed to be 
limited to developing countries, currently it is known 
that this infection has a worldwide distribution with 
different epidemiological patterns[9]. In developing 
countries where the infection is endemic, acute 
outbreaks or large epidemics of hepatitis E occur 
due to contamination of water supplies mainly at 
the time of heavy rainfall or following floods. These 
outbreaks are largely due to genotypes 1 and 2 and 
more frequently affect young adult males[1,3,5,8,9,18]. 
Whereas in developed countries, HEV infection is 
non-endemic and mostly occurs as sporadic locally-
acquired disease due to consumption of contaminated 
food supplies. The infection is due to genotypes 3 and 
4 and predominantly found among middle-aged elderly 
males throughout the year[1,3,5,9,18].
Apart from variations in the global epidemiological 
patterns of HEV, there is a wide range of variation 
in the prevalence and epidemiology of HEV infection 
within a country[5,16,35,36]. These variations reflect 
differences in the lifestyle, status of public health, risk 
factors, and routes of transmission in different regions 
and groups[35-37]. It is therefore necessary to review the 
epidemiology of HEV infection to determine the most 
prevalent risk factors and routes of transmission and 
to evaluate the effectiveness of prevention strategies 
employed in the public health services of a country. 
These epidemiological studies are not only essential for 
improving the current strategies to minimize the risk 
of acquiring HEV infection in the society but also clarify 
the real burden of HEV infection. 
This study has the objective to review the epidemiology 
of hepatitis E in Iran, a vast country located in the Middle 
East, with an extension of about 1700000 km2 and 
an estimated population of 70 million inhabitants in 
different provinces with various ethnicities[38].
HEV IN GENERAL POPULATION
With an overall prevalence rate of more than 5% 
in the general population, Iran is considered as an 
endemic country for HEV infection[36,39]. However, the 
seroprevalence of hepatitis E in the general population 
varies considerably in different parts of the country, 
ranging from 0.0% to 0.9% for anti-HEV IgM and 
1.1% to 14.2% for anti-HEV IgG and the total HEV 
antibodies in different studies[35,39-46] (Table 1[35,39-46]). 
Differences in the lifestyles, risk factors, levels of 
exposure, the geographic regions, study population, 
study periods, sample sizes, time of sampling, and 
the diagnostic accuracy of kits used to determine anti-
HEV antibodies in various studies can explain these 
variations[35-37]. However, the role of public health 
services, hygienic conditions, socioeconomic status, and 
environmental factors should not be dismissed[36,37,42]. 
The predominant mode of transmission in Iran is 
fecal-oral route, especially feces-contaminated drinking 
water; however, the other routes of transmission 
might also have a minor role in the spread of HEV but 
with undetermined importance[35,43,47]. Food-borne 
transmission of zoonotic origin is unlikely, since wild 
animal hunting and swine farming are prohibited 
in Iran[35]. Person-to-person transmission is most 
likely rare in Iran, since no association between the 
household size and seroprevalence rate of HEV has 
been reported[42]. Overall, the importance of the other 
probable routes of transmission in spread of HEV 
infection in the society still requires to be determined. 
Despite the epidemiological pattern in developing 
countries, where HEV most often affects young 
adults[1,5,9], the seroprevalence rate in Iran increases 
with age due to cumulative exposure to HEV over time 
with the highest prevalence rate among middle-aged 
and elderly individuals aged over 50 years[35,36,40,41,45]. 
Another possible reason is improvement in public 
hygiene, sanitation, sewage disposal and drinking 
water supply systems, which has resulted in decreased 
prevalence of HEV infection in young population of the 
country over time[36,47]. 
Except two reports[44,45], in the majority of studies, 
the seroprevalence of HEV was higher in females 
compared to males. However, none of these differences 
were significant[35,36,39-42]. In rural areas, inhabitants 
were more likely to be positive for HEV serological 
markers compared to individuals living in urban 
areas[39,43]. Appropriate access to the public health 
services, sewage disposal systems, and safe water 
supplies in cities can explain these differences in 
the seroprevalence rates regarding the place of 
residence[35,37,43]. Taken together, in studies from Iran, 
socioeconomic status, level of sanitation, population 
density, age, level of education, and place of residency 
were found to be risk factors for acquiring HEV 
infection in the society[35,42,43,48]. 
In one study from Iran, the prevalence of anti-HEV 
IgG antibody in the general population was as high as 
46.1% in South-West of the country[36]. The reason of 
this high endemicity is most likely Karun River as the 
drinking water source of the inhabitants, where the 
city sewage is also discharged in. It is also worthy to 
note that the participants in the mentioned study were 
all adults, mostly middle-aged and elderly adults[36]. 
Iran is located in the Middle East between HEV high 
endemic countries on the eastern and western borders. 
This considerable geographic location has affected 
epidemiological pattern of HEV infection in Iran[35,47]. 
A few occasional waterborne outbreaks of hepatitis 
E have also occurred in Iran[47]. The first documented 
outbreak was reported in Kermanshah city, West of 
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infection if HEV RNA is detected[1,16]. Some patients in 
viremic phase of infection do not show anti-HEV IgM 
responses[49]. Majority of risks are due to the presence 
of HEV RNA in blood of apparently healthy donors with 
normal levels of liver enzymes and negative anti-HEV 
IgM, which is indicative of asymptomatic viremia[7,18]. 
In these instances, blood transfusion is capable of 
trasmitting HEV infection despite negative serological 
markers. Therefore, HEV is a potential threat to blood 
safety[7,18]. 
Since 2005, Japan has implemented HEV RNA 
testing of all donors along with screening for elevated 
liver enzymes levels[7]. While some other countries 
perform selective HEV screening for high-risk reci-
pients[8]. The necessity to screen all blood donations or 
at least a part of them for HEV infection needs to be 
considered in Iran.
Studies on the seroprevalence of HEV in blood 
donors are limited in Iran and mainly have been 
conducted in main cities, while the seroprevalence 
varies from 4.5% to 14.3% in these studies[49-55] (Table 
1[49-55]). Despite this high prevalence, screening of blood 
donors for HEV is not performed in the blood banks of 
Iran until more evidence becomes available regarding 
the potential threat of HEV to blood safety[49,53]. In 
addition, the risk of incidence and transmission of 
hepatitis E by blood transfusion in Iran is unknown. 
Since the studies in Iran have only reported the rate 
of seropositivity, which is incapable of estimating 
the rate of viremic blood donors[49,53]. Therefore, 
additional studies to investigate the possibility of HEV 
transmission through blood transfusion seem to be 
necessary. Even if the risk of transmission through 
blood transfusion is low, we should not neglect the 
importance of this infection. Since HEV causes serious 
consequences in high-risk recipients, who often require 
blood transfusion. Therefore, access to HEV-free blood 
and blood products is the highest priority for this group 
of patients[4,7,18,50]. 
The seroprevalence of HEV among hemophilia and 
thalassemia patients in Iran is lower than expected and 
is in the range of that found in the general population 
of Iran[56]. The reason of this low prevalence may be 
that the blood donor population in Iran has mostly 
been consisted of young individuals, while HEV mostly 
affects middle-aged or old population in Iran[49,50,54]. 
This suggests that blood transfusion may not be a 
risk factor for transmission of HEV infection among 
hemophilia and thalassemia patients in Iran[56]. Still, 
more studies are required to confirm this issue. 
HEV IN INJECTING DRUG USERS
With having approximately 180000 injecting drug 
users (IDUs) among Iranian adults aged 15-64 years, 
Iran is considered one of the countries with the highest 
numbers of injection drug users in the world[38]. While 
only two studies have assessed the possible effect 
of injecting drug use on the seroprevalence of HEV 
among IDUs in Iran[57,58]. Alavi et al[57] reported high 
seroprevalence of HEV in IDUs (22.8%) compared 
to inhalant drug users (9.1%) and oral opiate drug 
users (6.2%) and suggested an association between 
injection drug abuse and HEV seropositivity in Ahvaz 
in 2005-2006. While some other studies from France, 
the United States (US), and Denmark have rejected 
this association[59-62]. Keramat et al[58] reported high 
prevalence of HEV in IDUs (6.1%) compared to non-
IDUs control group (1.5%) and found no relationship 
between duration of injection and HEV seroprevalence 
in Hamadan in 2011-2012.
These studies indicated high seroprevalence of 
HEV infection among IDUs in Iran[57,58], while this 
seroprevalence was not influenced by the type of 
substance abused but was associated with the route 
of administration[57]. According to the results of these 
studies, IDUs in Iran are at risk of acquiring HEV 
infection most likely due to exposure to infected blood 
through sharing syringe[58]. As a result, injection 
drug use was proposed as a possible route of HEV 
transmission. However, still more investigations are 
required to confirm this issue.
HEV IN HEMODIALYSIS PATIENTS
The seroprevalence of hepatitis E among patients on 
maintenance hemodialysis (HD) varies considerably 
from 4% to 28.3% in different cities of Iran[63-69] (Table 
1[63-69]). The reason of this vast geographic variation 
in different HD centers is unknown, but it may be due 
to the different levels of safety strategies in HD units, 
as well as the public health and prevalence of HEV 
infection in the community[30,64,69]. In some studies, 
HEV seroprevalence in HD patients is lower than or 
in the range of HEV seroprevalence in the general 
population of Iran[64,65,67], indicating a low risk of 
exposure to HEV in these areas or maybe a negligible 
HEV transmission in HD centers. While in some other 
studies, it is noticeably higher than HEV seroprevalence 
in the general population, which may be indicative 
of parenteral transmission of HEV infection[30,63,66,69]. 
Similar high prevalence of anti-HEV antibodies in HD 
patients has been reported in Egypt (22.9%)[70], Japan 
(30%)[71], and Turkey (20.6%)[72]. In contrast, reports 
from Italy (6.0%)[73], Brazil (6.2%)[74], and Spain 
(6.3%)[75] have indicated a low seroprevalence of HEV 
among HD patients. 
The seroprevalence of HEV infection among Iranian 
HD patients was associated with almost no risk factor 
in most of these studies[63,64,67,68]. While duration of HD 
was significantly associated with HEV seropositivity in 
two studies[65,69]. In addition, in one study, 41.7% of 
HEV seropositive HD patients had a history of blood 
transfusion[69]. These studies support the nosocomial 
transmission of HEV infection[30,47,65]. While the others 
indicate a rare acquisition of HEV infection through 
hemodialysis[64,67]. Overall, the epidemiology of HEV 
infection among HD patients in Iran seems to be 
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a controversial issue due to these variations in the 
results of so far conducted studies. Therefore, more 
extensive or comprehensive studies in different 
geographical regions of Iran are required to resolve 
these conflicts between the results and to determine 
the exact epidemiological pattern of HEV infection 
among HD patients.
Considering the clearance of a significant level of anti-
HEV antibodies during the process of dialysis as well as 
weak antibody responses due to chronic renal disease, a 
considerable proportion of HEV seropositive HD patients 
may be reported as seronegative[30,67,69,76-81]. Except one 
study[65], the serum levels of liver enzymes were normal 
or low in HEV seropositive patients on maintenance 
hemodialysis due to the fast reduction of these enzy-
mes to the normal levels[30,67]. Therefore, some HEV-
infected HD patients may remain undiagnosed. These 
HD patients with inapparent HEV infection might be 
the main source of HEV transmission as a nosocomial 
infection in HD units[30]. Overall, neither anti-HEV 
antibodies nor level of liver enzymes can be valid 
diagnostic markers in case of HEV infection among HD 
patients[30]. Therefore, serious safety measures and 
proper screening of HD patients for hepatitis E in HD 
centers should be considered to prevent transmission 
of HEV during the process of hemodialysis.
HEV IN PATIENTS INFECTED WITH 
OTHER HEPATITIS VIRUSES
Viral hepatitis infections are believed to be associated 
with an increased risk of hepatitis E occurrence, and 
co-infection or superinfection with HEV will enhance 
the risk of liver failure[11,17,82,83]. In recent years, several 
studies have reported high prevalence of hepatitis 
E among patients with chronic viral hepatitis and 
supported the possibility of parenteral transmission of 
HEV[30,82,84], while other studies have demonstrated a 
low occurrence of these co-infections or superinfections 
and found no association between HEV and other 
viral hepatitis[85,86]. This variation in the prevalence 
of HEV among patients with other viral hepatitis 
reflects differences in the routes of transmission and 
distribution of these hepatotropic viruses in different 
parts of the world. Although HEV is predominantly 
transmitted via the fecal-oral route, the possibility 
of parenteral transmission has also been reported in 
endemic countries[82,87].
Currently, only a few reports are available regarding 
the prevalence of HEV infection among patients with 
viral hepatitis in Iran. Keyvani et al[51] reported high 
prevalence of anti-HEV antibody in HBV (11.3%) and 
HCV (7%)-infected patients compared to healthy 
blood donors (4.5%) in Tehran. In another study 
by Karimi Elizee et al[56], the seroprevalence of HEV 
among thalassemia and hemophilia patients with 
chronic hepatitis C was reported to be 1.6% and 3.2%, 
respectively, which is similar to HEV seroprevalence in 
Iranian general population. Kelishadi et al[77] reported 
the absence of anti-HEV IgG antibody in GB virus 
C positive hemodialysis patients in Gorgan. These 
studies were unable to determine the effect of hepatitis 
E on the clinical outcomes of the other viral hepatitis. 
Overall, data concerning dual infection with hepatitis E 
and the other viral hepatitis in Iran are scarce, and the 
routes of HEV transmission in this group of patients 
are unclear. Therefore, further studies are required to 
determine the association between HEV and other viral 
hepatitis in Iran. 
HEV IN IMMUNOCOMPROMISED AND 
IMMUNOSUPPRESSED PATIENTS
HEV infection in immunocompromised and immuno-
suppressed patients may lead to chronic hepatitis 
E, with an increased risk of developing liver fibrosis 
and cirrhosis, and subsequently lower survival of 
the infected patients[9,10,27]. Chronic HEV infection is 
characterized by the persistent presence of detectable 
HEV-RNA in serum and stool for more than 6 mo (more 
than 3 mo in organ transplant recipient patients) 
along with persistently elevated liver enzymes[3,5,8,9,33]. 
So far, chronic hepatitis E has been observed in HIV-
infected patients, organ transplant recipient patients, 
and those with hematological malignancies, who 
receive anticancer chemotherapy[5,10,25-27,88]. However, 
the possibility of HEV chronicization in other patients 
with immunosuppressive conditions is currently under 
investigation, and this chronic infection may identify in 
more categories of patients in near future[3].
More recently, some cases of chronic HEV infection 
have also been observed in elderly immunocompetent 
individuals[8]. While no report of chronic infection has 
been documented in pregnant women and infants[16,28]. 
Almost all cases of chronic hepatitis E have been 
observed following infection with HEV genotype 
3[3,5,7,25]. The first case of chronic hepatitis E caused 
by HEV genotype 4 has recently been identified in a 
Chinese patient[3,9]. 
The seroprevalence of hepatitis E among organ 
transplant recipient patients varies from 2.3% to 
43.9% in different studies[5]. While the prevalence 
of HEV infection based on the detection of viral 
RNA ranges from 0.9% to 3.5%[5]. This prevalence 
among transplant recipient patients with elevated 
liver enzymes is 4.3%-6.5%[5]. The chronicity 
rate of hepatitis E is approximately 60% in organ 
transplant recipient patients without therapeutic 
interventions[25,26,30]. 
Indeed, progression to chronicity in immuno-
compromised patients could be mediated by inability 
to clear the virus after acute infection, which is related 
to the degree of immunosupression and immunological 
status of transplant recipient patients at the time of 
HEV infection as well as the time period between the 
transplantation and incidence of HEV infection[3,5,10,29].
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Therefore, suboptimal HEV-specific cellular 
immune responses, low lymphocyte and platelet 
counts, the occurrence of HEV infection immediately 
after transplantation, and the use of more effective 
immunosuppressive drugs such as tacrolimus are 
risk factors for the incidence of chronic hepatitis E in 
immunocompromised patients following exposure 
to HEV[1,3,5,26,88]. Even the presence of anti-HEV IgG 
antibodies prior to re-exposure to HEV cannot exclude 
the chance of reinfection in transplant recipient 
patients, and such reinfections may lead to chronic 
infection[3]. The main route of HEV transmission in 
immunocompromised patients seems to be fecal-oral, 
especially via consumption of contaminated food[3,5,16]. 
However, acquisition of HEV infection following blood 
transfusion and liver transplantation is also possible 
but seems to be uncommon[3,5,26]. Most patients 
with chronic hepatitis E are asymptomatic, and the 
rest show nonspecific symptoms, including fatigue, 
fever, abdominal pain, asthenia, and very rarely 
jaundice[5,25]. Chronic hepatitis E can rapidly progress 
to liver fibrosis, cirrhosis, and subsequently fatal 
liver failure in immunocompromised patients[3,5,25]. In 
addition, numerous hepatitis E-associated extrahepatic 
manifestations, including neurological, hematological, 
musculoskeletal, renal manifestations, as well as acute 
pancreatitis, autoimmune thyroiditis, myocarditis, 
mixed cryoglobulinemia, thrombocytopenia, arthralgia, 
Henoch-Schonlein purpura, myasthenia gravis, hae-
molysis, membranous glomerulonephritis associated 
with immunological disorders and many others have 
been reported in patients with acute or chronic HEV 
infection[7,9,25,33,89,90]. 
Such extrahepatic complications sometimes 
outshine clinical manifestations of hepatic injury, 
and the causative agents, hepatitis E, might not be 
suspected. Therefore, the probability of hepatitis E in 
extrahepatic manifestations should be considered[33]. 
Chronic hepatitis E results in graft loss and 
subsequently retransplantation in organ transplant 
recipient patients. However, recurrent hepatitis E 
and subsequently progressive chronic infection after 
retransplantation may also occur if the viral clearance 
is not achieved before retransplantation[5].
In this situation, early diagnosis of hepatitis E 
in this group of patients is the highest priority. The 
diagnosis should be based on the detection of HEV 
RNA in serum, cerebrospinal fluid (CSF) in case of 
neurological complications or stool samples, not levels 
of liver enzymes and results of serological tests[3,26,33,91]. 
Since various factors can elevate liver enzymes, 
including drugs, toxin, graft rejection, infections, and 
biliary tract dysfunction[30]. Furthermore, the presence 
of chronic HEV infection in organ transplant recipient 
patients is sometimes accompanied by normal liver 
enzymes[30]. In addition, the delay or absence of 
seroconversion and loss of anti-HEV antibodies are 
frequently observed in this group of patients due 
to immunosuppressive conditions, which result in 
suppression of antibody development over time[5,91]. 
Therefore, immunocompromised or immunosuppressed 
patients with chronic HEV infection may have normal 
liver enzymes and negative serological tests[26,30,81].
In these conditions of uncertainty, the awareness 
of physicians regarding chronic HEV infection is crucial. 
Since most cases of chronic HEV infection may be 
missed due to the lack of HEV consideration among 
physicians or inappropriate choose of diagnostic 
assays[3,25].
Reports on HEV prevalence in immunocompromised 
patients in Iran are scarce. Rostamzadeh Khameneh 
et al[81] assessed the seroprevalence of HEV among 91 
Iranian kidney transplant recipient patients. Overall, 
the seroprevalence of HEV was 30.8%. Joulaei et al[80] 
reported a HEV seroprevalence of 16.4% among 158 
HIV-infected individuals in Shiraz in 2013. In another 
study by Ramezani et al[79], the seroprevalence of 
HEV infection was found to be 10% among 100 HIV-
positive individuals in Tehran in 2012. These limited 
studies were unable to determine the incidence 
and prevalence of chronic HEV infection among 
immunocompromised patients in Iran. Since only the 
seroprevalence of anti-HEV IgG antibodies has been 
assessed, while HEV-RNA has not been measured 
in these studies[81,88]. Therefore, more studies are 
required to gain insight into the burden of chronic HEV 
infection in Iran.
CONCLUSION
However, Iran is classified as an endemic region 
for HEV infection, but we do not know much about 
this infection in Iran. The available epidemiological 
data have demonstrated the seroprevalence of HEV 
infection in different groups and regions of Iran, while 
the presence of HEV-RNA has not been evaluated 
in the studies published so far. In addition, the 
distribution pattern of HEV genotypes is unknown in 
Iran. 
From historical aspect, hepatitis E is not new 
in Iran but is underestimated due to the lack of 
awareness amongst physicians and inappropriate 
diagnosis of the infection. The importance of HEV 
infection as a main public health problem cannot 
be neglected any longer. The identification of HEV-
associated extrahepatic manifestations and chronic 
hepatitis E in immunocompromised patients has 
attracted attention to the study of HEV in recent years. 
While these new aspects of so thought acute self-
limited hepatitis remain unknown in Iran. Overall, still 
a long way is ahead to determine the epidemiological 
patterns of HEV in Iran. To approach this goal, further 
epidemiological investigations at the national level 
are needed to more clearly delineate the incidence 
and prevalence of HEV infection in Iran. In addition, 
nationwide efforts should be pursued to control and 
prevent HEV infection in Iran. 
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